CytoDyn to present updated Phase 2 CLOVER trial data for leronlimab combo in metastatic colorectal cancer at ESMO 2026

PUBT · 3d ago
CytoDyn to present updated Phase 2 CLOVER trial data for leronlimab combo in metastatic colorectal cancer at ESMO 2026
  • CytoDyn flagged updated clinical data from its Phase 2 CLOVER trial in metastatic colorectal cancer for presentation at ESMO Congress 2026.
  • Results have not yet been presented; the update is scheduled for Oct. 25, 2026, in Madrid.
  • The study evaluates leronlimab alongside established therapies in previously treated patients, aiming to improve outcomes in hard-to-treat disease.
  • Management framed the update as supporting its strategy to advance leronlimab in combination regimens across solid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080830PRIMZONEFULLFEED9841888) on October 08, 2026, and is solely responsible for the information contained therein.